NCT00545584View on ClinicalTrials.gov

Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,512

Participants

Timeline

Start Date

April 1, 2007

Primary Completion Date

November 19, 2009

Study Completion Date

November 19, 2009

Conditions

Diabetes Mellitus, Non-Insulin-Dependent

Interventions

DRUG

sitagliptin phosphate

sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks

BEHAVIORAL

Comparator: Diet

Diet

BEHAVIORAL

Comparator: Physical Activity

Physical Activity

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00545584 - Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078) | Biotech Hunter | Biotech Hunter